x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243207
| Product Information | |
|---|---|
| CAS No. | 2289739-47-3 |
| Formula | C23H32N4O4 |
| Molecular Weight | 428.52 |
| SMILES | O=C(N1CCC2(CCN(CC2)C3=C4C=C(OC)C(OC)=CC4=NC=N3)C1)OC(C)(C)C |
| Target | Phosphodiesterase (PDE) |
| Product Description | Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | Off-white to light yellow |
| Purity | 99.11% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years In solvent: -80°C, 6 months; -20°C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
